OncoSil Medical is pleased to announce a A$10 million Institutional Placement (Placement) to drive commercialisation of the Company's lead product candidate, the OncoSillocalised radiation treatment for cancer.
The Placement is by way of Subscription Agreement for approximately 45,454,545 new Ordinary Shares in OncoSil Medical at a price of $A0.22 per share to raise $10 million.
The Company is delighted to receive this level of investment and financial backing at this point in time, and views it as strong validation for the OncoSil brachytherapy technology and its global commercialisation potential.
To view full announcement, please click here: OncoSil Medical Capital Placement